NDAORALTABLET
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XTRELUS is an oral tablet combining guaifenesin (expectorant) and hydrocodone bitartrate (opioid cough suppressant) approved in April 2018. It is indicated for cough suppression and mucus clearance in respiratory conditions. The fixed-dose combination leverages hydrocodone's CNS-mediated antitussive effect paired with guaifenesin's mucolytic activity.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%); teams are likely focused on maintaining market share and operational efficiency rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XTRELUS has zero linked job openings, indicating a mature, stable commercial footprint with minimal hiring. Careers on this product are best suited for professionals seeking established brand management, field execution, or regulatory maintenance roles rather than growth or development opportunities.
Brand ManagerProduct Manager
Worked on XTRELUS at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.